Effects of Low-Dose Cisplatin on 89Sr Therapy for Painful Bone Metastases from Prostate Cancer: A Randomized Clinical Trial

This study evaluated the effects of low-dose cisplatin plus 89Sr versus 89Sr alone in the treatment of painful bone metastases from prostate cancer, addressing both pain palliation and cyto-static effects. Methods: Seventy patients with metastatic hor-mone-refractory prostate cancer were randomized into 2 groups: One group (arm A) received 148 MBq 89Sr plus 50 mg/m2 cisplatin, and the other group (arm B) received 148 MBq 89Sr plus placebo. After treatment, the patients were followed up until death to evaluate the outcome variables: grade and dura-tion of pain palliation, onset of new painful sites, changes in bone disease, global survival, serum prostate-specific antigen and alkaline phosphatase changes, and hematologic toxicity. Results: Overall pain relief occurred in 91 % of patients in arm A and 63 % of patients in arm B (P 0.01), with a median duration of 120 d in arm A and 60 d in arm B (P 0.002). New painfu